✉news BusinessStartups first seen 18 h ago, last 7 h ago, peak #5
Immunotherapy startup Adecto shuts down, blaming funding climate
Original: Immmunotherapy startup Adecto blames ‘risk-adverse funding environment’ for closing down
Immunotherapy startup Adecto is closing down, with the company attributing its collapse to what it calls a risk-averse funding environment. The announcement underscores the continued pressure on early-stage biotech firms as investors pull back from unproven therapeutic platforms, leaving promising research pipelines without the capital needed to advance into clinical development.
Why now: The shutdown highlights ongoing difficulties biotech startups face raising money in a cautious investment climate.
Rank over time, top of the chart is #1. 14 snapshots from 18 h ago to 7 h ago.
Evidence
- Immmunotherapy startup Adecto blames ‘risk-adverse funding environment’ for closing down · Fierce Biotech
API: https://socialmediatrends-api.osmike.com/v1/trends/720347